XML 54 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
Net Loss Per Share (Details) - USD ($)
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (23,085,907) $ (8,042,820)
Reflect adjustment for decrease in fair value of warrant liability (116,477) 0
Numerator for use in diluted loss per share $ (23,202,384) $ (8,042,820)
Weighted average number of common shares outstanding (shares) 74,152,609 72,230,411
Effect of dilutive potential common shares (shares) 148,275 0
Denominator for use in diluted loss per share (shares) 74,300,884 72,230,411
Net loss per share, diluted ($ per share) $ (0.31) $ (0.11)
Antidilutive securities excluded (shares) 9,227,018 8,437,652
Options to purchase commons stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (shares) 7,841,669 7,135,624
Warrants to purchase common stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (shares) 0 560,904
Restricted stock units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (shares) 1,376,893 732,668
Convertible preferred stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded (shares) 8,456 8,456